Within the final week of December, whereas many of the U.S. was nonetheless in vacation mode, Novo Nordisk’s plant in North Carolina was working at full capability.
On Dec. 22, the U.S. Meals and Drug Administration (FDA) accredited the corporate’s oral model of Wegovy, making it the primary tablet of the favored GLP-1 medicines to get the inexperienced gentle for weight reduction. Individuals who need to drop a few pounds and are prescribed Wegovy now have the choice of taking the pill every day, versus injecting themselves with the drug as soon as per week. They’ll lose about the identical quantity of weight with both model: between 16% and 17% of their beginning physique weight.
The plant, simply outdoors of Raleigh, is working across the clock to provide bottles of tablets in 4 totally different doses. The bottles are certain for retail shops and on-line pharmacies and can be obtainable beginning on Jan. 5. “Weight problems has grow to be a consumer-oriented illness,” stated Novo Nordisk’s CEO Mike Doustdar in an interview with TIME. “We’re embracing that.”
The corporate’s total provide of the drug, from begin to end, can be manufactured in North Carolina. Days earlier than the launch of Wegovy tablet, TIME visited the plant to observe how the primary Wegovy tablets are being produced, bottled, and packaged for sufferers.
All of it begins with yeast
Wegovy tablet begins with a fungus: particularly, the identical yeast used to make bread, referred to as Saccharomyces cerevisiae. However as a substitute of fermenting sugars or grains to make bread rise, the yeast cells are genetically engineered at Novo Nordisk’s facility in Clayton, North Carolina to provide a protein that undergoes fermentation in a number of four-story tall tanks, then a number of purification steps over a few month to provide semaglutide, a compound that mimics a human hormone that regulates urge for food by working within the reward middle of the mind. It could assist folks really feel full and cut back emotions of starvation.
Harvesting the primary ingredient
After the fermentation and purification course of, semaglutide types a beige paste with the consistency of pancake batter. In one of many few guide steps within the largely automated manufacturing, technicians scrape the paste from massive funnels and freeze it at -20°C, the place it retains for as much as 5 years. However given the recognition of Wegovy and the anticipated demand for the tablet, the corporate at the moment has a few month’s provide of semaglutide in its freezers.
Taking tablet type
Within the remaining step of the method, the paste is thawed and purified right into a liquid at a excessive temperature. That heated liquid is then spray-dried right into a high quality white powder, much like the way in which snow-making machines flip sizzling water into snow. That powder, collected in massive luggage from a funnel that extends via three flooring, is then pressed into Wegovy tablets.
A protracted path to the tablet
Whereas this semaglutide tablet is the primary to deal with weight problems, it isn’t the primary that Novo Nordisk has made. The corporate’s scientists first grew to become excited about semaglutide as a diabetes remedy since it may additionally assist management blood glucose, and its first semaglutide-based remedy, Ozempic, was accredited in 2017 for diabetes. Sufferers injected themselves as soon as per week to regulate blood sugar, however to make taking the drug simpler, the corporate additionally developed a tablet type, referred to as Rybelsus, which the FDA accredited in 2019. Turning Ozempic into an oral tablet required discovering a approach to defend the drug from the hostile surroundings of the abdomen simply lengthy sufficient for it to be absorbed by the physique. “However with numerous these methods, it could trigger an excessive amount of permeability—so issues that shouldn’t be absorbed, like micro organism or different issues, have been absorbed,” says Andrea Traina, senior medical director for weight problems and liver well being at Novo Nordisk. The scientists finally discovered a approach to create a chemical buffer to defend the drug whereas it launched sufficient semaglutide to be efficient. Nonetheless, as a result of the tablet has to undergo the abdomen and digestive tract, it’s usually not as efficient because the injected Ozempic.
When diabetes sufferers observed they have been losing a few pounds on semaglutide, Novo Nordisk and different firms started to check the compound for its potential results on weight problems. Research confirmed what these sufferers have been experiencing, and in 2021, the FDA accredited Novo Nordisk’s Wegovy to deal with weight problems. However folks nonetheless needed to inject themselves with the remedy to learn from its results. Creating the Wegovy tablet grew to become the subsequent problem, and the identical hurdles the corporate confronted in creating Rybelsus remained. However this time, the researchers developed a proprietary fatty acid spinoff to raised navigate the tough surroundings of the abdomen. “After you swallow the pill, it is available in contact with the abdomen lining and begins to dissolve and create a foamy microenvironment across the tablet,” says Traina. “Image an Alka-Seltzer pill dissolving in water.” The response quickly inhibits abdomen enzymes within the space from breaking down the drug, which provides the semaglutide sufficient time to be absorbed. “The entire course of takes about half an hour,” she says, after which period “the microenvironment of the abdomen goes again to regular.” To maximise the tablet’s potential to soak up, folks taking it ought to swallow it very first thing within the morning on an empty abdomen with as much as half a glass of water with no meals, drinks, or different medicines for not less than half-hour, the corporate advises, so nothing will intervene with the tablet’s exercise.
Stiff competitors
Wegovy tablet shouldn’t be the one GLP-1 weight-loss tablet on the horizon. Eli Lilly, which makes the injectable GLP-1 medicine Mounjaro for diabetes and Zepbound for weight reduction (utilizing the energetic ingredient tirzepatide) has developed a tablet referred to as orforglipron. In December, the corporate launched optimistic knowledge displaying its tablet may assist folks preserve weight reduction after utilizing injected types of GLP-1 medicine for greater than a 12 months and submitted a request to the FDA for approval. The company granted orforglipron a precedence voucher in November, that means the FDA will conduct an expedited overview in order that tablet can come to market a lot quicker than the everyday drug.
Novo Nordisk and Eli Lilly have been locked in a GLP-1 competitors for years. Some analysis has discovered that Lilly’s drug Zepbound results in better weight reduction—as much as 21% of physique weight—in comparison with 15% on Wegovy. “The distinction may be very largely linked to doses,” says Doustdar; the best dose tirzepatide is larger than that of semaglutide in Wegovy. For that cause, Novo Nordisk is creating the next dose of Wegovy within the injectable type that produces comparable quantities of about 20% weight reduction. “We can be bringing Wegovy-Plus into the market [in 2026] so it should shut the hole with our competitor,” he says.
He additionally sees semaglutide as the corporate’s “secret sauce” that appears to provide various well being advantages. It’s the one GLP-1 drug that the FDA permits to assert on its label advantages forthat coronary heart illness and sure liver situations profit. Whereas latest analysis discovered that the compound didn’t gradual Alzheimer’s illness, as many had hoped it could, the drug’s potential to cut back irritation may result in extra well being advantages in different metabolic illnesses.
Doustdar, who was appointed to move Novo Nordisk final summer time as the corporate started dropping market share within the GLP-1 house to Eli Lilly, sees Wegovy tablet as a coup for the corporate—and a return to specializing in diabetes and weight problems. “It is a huge illness space. We’re speaking about two billion folks, and finally, somebody has to provide all of the doses for them. We’re sitting in the correct spot proper now [to do that], and nonetheless solely touching a fraction of the people who find themselves in want.”
Choices for the tablet
In coming weeks, Wegovy tablet can be obtainable in 4 doses: a starter dose of 1.5 mg, in addition to 4 mg, 9 mg, and 25 mg. As with injectable Wegovy, most sufferers will begin with the bottom dose and regularly ramp up their dosage over a interval of months till they attain the utmost dose, which they’ll proceed to take care of their new weight.
As the corporate and the White Home introduced in November, the starter dose will value $149 for a month’s provide for folks paying out-of-pocket and utilizing federal insurance policy. The subsequent-highest dose can be $149 till April 2026, after which it should enhance to $199 a month. The 2 highest doses will value $299 for a month’s price of tablets. Individuals with insurance policy that cowl the tablets could pay as little as $24 for a 30-day provide.
Doustdar says the White Home announcement was the results of a number of months of dialogue to achieve a mutually agreeable worth plan for the drug. “For us to have the ability to make any offers, it has to not be a zero-sum sport, however a win-win scenario,” he says. “We would have liked to clarify that the price of operations within the U.S. may be very totally different from the price of operations in Europe.”
“Alternatively, we additionally acknowledge that at increased costs, we is not going to get entry to larger volumes,” he says—and with a whole bunch of tens of millions of individuals all over the world who may doubtlessly profit from a weight-loss drug, Doustdar hopes Wegovy tablet can be extra handy, and accessible, for them.
Discussion about this post